期刊文献+

世界一代畅销名药阿托伐他汀的开发应用进展 被引量:5

下载PDF
导出
摘要 阿托伐他汀(INN:Atorvastatin,Pfizer公司商品名:Lipitor)是降低血液胆固醇水平的常见药物。由辉瑞公司生产制造,销售商品名为胆固清或立普妥(Lipitor)。它是一种他汀类药物,用于降低血液中的胆固醇。它还可稳定血液斑块和预防中风。类似于所有他汀类药物,阿托伐他汀通过抑制肝组织中,一种对胆固醇制造起关键作用的酵素——羟甲基戊二酸单酰辅酶A还原酶(HMG-Co A reductase),以减少体内制造胆固醇。
作者 刘浩
出处 《黑龙江医药》 CAS 2015年第3期491-495,共5页 Heilongjiang Medicine journal
  • 相关文献

参考文献3

二级参考文献50

  • 1于建刚,钱建东,徐红,袁雪芬,徐丽芳,朱建琴.阿托伐他汀钙对脑梗死患者颈动脉斑块影响的临床研究[J].华西医学,2008,23(6):1305-1306. 被引量:14
  • 2蔡正艳,宁奇,周伟澄.HMG-CoA还原酶抑制剂的合成(上)[J].中国医药工业杂志,2004,35(10):621-626. 被引量:5
  • 3蔡正艳,宁奇,周伟澄.HMG-CoA还原酶抑制剂的合成(下)[J].中国医药工业杂志,2004,35(11):687-691. 被引量:5
  • 4邸晓辉,杨永革,梅巍,刘静,许雪廷.阿托伐他汀钙胶囊的人体生物等效性研究[J].解放军药学学报,2005,21(4):262-265. 被引量:8
  • 5MARITIM AC, SANDERS RA,WAT KINS JB. Diabetes, oxidative stress and antioxidants [ J ]. Biochem Mol Toxicol, 2003,17 (1) :24 -38.
  • 6GRAWEL S,WARDAS M, WOROKE N,et al. Malondialdehyde (MDA) as a lipid peroxidation marker[ J]. Wiad Lek,2004,57 (9 - 10) :453 -455.
  • 7SONG YB,ON YK, KIM JH,et al. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off2pump coronary artery bypass grafting surgery [ J ]. Am Heart J, 2008, 156(2) :9 -16.
  • 8TSAI CT,LAI LP,HWANG JJ,et al. Atorvastatin prevents atrial fibrillation in patients with bradyar rhythm ias and implantation of an atrial-based or dual-chain-bet pacemaker: a prospective randomized trial [ J ]. Am Heart J, 2008,156 ( 1 ) : 65 - 70.
  • 9GILLIS AM,MORCK M,EXNER DV,et al. Beneficial effects of statin therapy for prevention of atrial fibrillation following DDDR pacemaker imp lantation [ J ]. Eur Heart J, 2008,29 ( 15 ) : 1873 - 1880.
  • 10LEE SH,CHUNG N,KWAN J,et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin : an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia [ J ]. Clin Ther, 2007,29 ( 11 ) :2365 -2373.

共引文献109

同被引文献41

  • 1盖永浩,宋树良.动脉粥样硬化的超声评价指标[J].临床超声医学杂志,2005,7(3):192-194. 被引量:36
  • 2姜怡邓,曹军,董泉洲,王树人.PKC和MMPs在枸杞籽油抗动脉粥样硬化中的作用和机制[J].华西药学杂志,2007,22(1):9-12. 被引量:5
  • 3VARGO R,ADEWALE A,BEHM MO,et al. Prediction of clini- cal irrelevance of PK differences in atorvastatin using PK/PD models derived from literature-based meta-analyses [ J ]. Clin Pharmacol Ther ,2014 ,96 ( 1 ) : 101 - 109.
  • 4PATRICIA K, JOACHIM K,ISABEL F, et al. Measurement of HMG-CoA reduetase activity in different human cell lines by ul- tra-performance liquid chromatography tandem mass spectrometry [ J ]. Biochem Biophys Res Commun,2014,443 (2) :641 - 645.
  • 5WALDRON J, WEBSTER C. Liquid chromatography-tandem mass spectrometry method for the measurement of serum mevalon- ie acid:a novel marker of hydroxymethylglutaryl coenzyme A re- ductase inhibition by statins [ J ]. Ann Clin Biochem, 2011,48 (3) :223 -232.
  • 6MACWAN JS,IONITA IA,DOSTALEK M, et al. Development and validationof a sensitive,simple,and rapid method for simulta- neous quantitationof atorvastatin and its acid and lactone metabo- lites by liquidchromatography-tandem mass spectrometry( LC-MS/ MS) [J~. Anal Bioanal Chem,2011,400(2) :423 -433.
  • 7GHOSH C, JAIN I, GAUR S, et al. Simultaneous estimation of atorvastatin and its two metabolites from human plasma byESI-LC- MS/MS[J]. Drug Test Anal,2011,3( 6) :352 - 362.
  • 8EL-KOMMOS ME, MOHAMED NA, ALIHR, et aL Micel- lar elcctrokinetie chromatographic determination of rosuvastatin in rabbit plasma and evaluation of its pharmaeokinetics and interac- tion with niacin [ J ]. Biomed Chromatogr, 2014,28 ( 12 ) : 1828 - 1838.
  • 9YANG Y,XU Q,ZHOU L,et al. High-throughput salting-out-as- sisted liquid-liquid extraction for the simultaneous determination of atorvastatin, ortho-hydroxyatorvastatin, and para-hydroxyatorv- astatin in human plasma using ultrafast liquid chromatography with tandem mass spectrometry [ J ]. J Sep Sei, 2015,38 ( 6 ) : 1026 - 1034.
  • 10《中国成人血脂异常防治指南》制订联合委员会编著.中国成人血脂异常防治指南(M)人民卫生出版社, 2007

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部